[{"id":"e9f712c9-43ca-4d3b-9a6c-4c80e514d787","acronym":"NCI-2018-01503","url":"https://clinicaltrials.gov/study/NCT03587311","created_at":"2021-01-29T07:17:35.675Z","updated_at":"2024-07-02T16:35:02.670Z","phase":"Phase 2","brief_title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03587311 - NCI-2018-01503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/12/2018","start_date":" 10/12/2018","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2024-05-17"},{"id":"09261b2f-42ac-4b72-856f-4daf46603021","acronym":"NCI10208","url":"https://clinicaltrials.gov/study/NCT03816358","created_at":"2021-01-18T18:51:22.211Z","updated_at":"2024-07-02T16:35:03.288Z","phase":"Phase 1","brief_title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03816358 - NCI10208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-16"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"afcec8a4-0dae-4657-8947-be495c4de8d2","acronym":"ARCS-Multi","url":"https://clinicaltrials.gov/study/NCT03102320","created_at":"2021-01-18T15:17:05.990Z","updated_at":"2025-02-25T15:53:43.857Z","phase":"Phase 1b","brief_title":"Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors","source_id_and_acronym":"NCT03102320 - ARCS-Multi","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 173","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 09/16/2020","primary_completion_date":" 09/16/2020","study_txt":" Completion: 07/26/2021","study_completion_date":" 07/26/2021","last_update_posted":"2022-06-30"},{"id":"f6ee17ab-5c37-4b9b-bd5b-1e4de5185e91","acronym":"","url":"https://clinicaltrials.gov/study/NCT03023722","created_at":"2021-01-18T14:52:45.385Z","updated_at":"2025-02-25T17:23:25.991Z","phase":"Phase 2","brief_title":"Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer","source_id_and_acronym":"NCT03023722","lead_sponsor":"Yale University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/11/2017","start_date":" 05/11/2017","primary_txt":" Primary completion: 08/06/2019","primary_completion_date":" 08/06/2019","study_txt":" Completion: 12/11/2019","study_completion_date":" 12/11/2019","last_update_posted":"2021-10-28"},{"id":"ac6ec01d-b71d-4682-9e1d-f6ff962816a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01439152","created_at":"2021-01-18T05:57:41.754Z","updated_at":"2025-02-25T17:19:27.903Z","phase":"Phase 1","brief_title":"Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT01439152","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 09/07/2011","start_date":" 09/07/2011","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 07/30/2019","study_completion_date":" 07/30/2019","last_update_posted":"2021-07-09"},{"id":"acff4e6b-c1c6-4653-bd5d-45a3bd8b6bce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02696642","created_at":"2021-01-29T07:11:49.765Z","updated_at":"2025-02-25T17:08:39.658Z","phase":"Phase 1","brief_title":"Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment","source_id_and_acronym":"NCT02696642","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 04/14/2016","start_date":" 04/14/2016","primary_txt":" Primary completion: 07/31/2018","primary_completion_date":" 07/31/2018","study_txt":" Completion: 08/19/2019","study_completion_date":" 08/19/2019","last_update_posted":"2021-07-09"},{"id":"fd0b0766-02cf-417f-b812-6dc78ce873ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02610140","created_at":"2021-01-29T07:11:14.871Z","updated_at":"2025-02-25T15:42:45.006Z","phase":"Phase 2","brief_title":"Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)","source_id_and_acronym":"NCT02610140","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • vinorelbine tartrate • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 12/03/2015","start_date":" 12/03/2015","primary_txt":" Primary completion: 05/31/2017","primary_completion_date":" 05/31/2017","study_txt":" Completion: 09/06/2019","study_completion_date":" 09/06/2019","last_update_posted":"2020-11-04"},{"id":"5aa8d102-2855-40de-9718-f6d3ba795d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639091","created_at":"2021-01-18T12:50:14.208Z","updated_at":"2025-02-25T17:08:34.139Z","phase":"Phase 1","brief_title":"Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors","source_id_and_acronym":"NCT02639091","lead_sponsor":"Bayer","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/03/2016","start_date":" 02/03/2016","primary_txt":" Primary completion: 05/23/2018","primary_completion_date":" 05/23/2018","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2019-11-07"},{"id":"927d067b-a2c8-45e8-b48f-882fec92e64b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02485119","created_at":"2021-01-18T11:58:19.477Z","updated_at":"2025-02-25T17:08:10.448Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies","source_id_and_acronym":"NCT02485119","lead_sponsor":"Bayer","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anetumab ravtansine (BAY 94-9343)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/14/2015","start_date":" 08/14/2015","primary_txt":" Primary completion: 04/28/2017","primary_completion_date":" 04/28/2017","study_txt":" Completion: 07/04/2017","study_completion_date":" 07/04/2017","last_update_posted":"2018-06-04"}]